Impact of different hold time before addition of platelet additive solution on the in vitro quality of apheresis platelets.
BACKGROUND
The quality of platelets (PLTs) stored in PLT additive solution (PAS) is dependent on the type and proportion of the used PAS. No data are available as to whether a different hold time before the addition of PAS to hyperconcentrated PLT suspensions has an impact on PLT quality. The in vitro quality between single-donor PLT concentrates was compared with two different hold times with two PASs.


METHODS
On two occasions, 6x10(11) PLTs in 150 mL of plasma were collected from 20 blood donors. The units were split into two equal parts, and 140 mL of PAS-II or PAS-IIIM (randomized sequence) was added after 2 or 8 hours resulting in a PAS proportion of 65 percent. On Days 1, 5, and 7, glucose and lactate concentration, pH value, PLTs' P-selectin expression, response to hypotonic shock, and release of transforming growth factor-beta1 were determined.


RESULTS
On all days, the lactate concentrations were higher and pH values were lower in units with an 8-hour hold time, whereas the results of in vitro tests relating to the in vivo viability and activation of PLTs were similar for both groups. PAS-IIIM-stored PLTs showed a lower glycolytic activity and better results in all performed in vitro tests than PAS-II-stored PLTs.


CONCLUSIONS
Although the metabolism of glucose was enhanced during hold time, the differences between both hold time groups are not meaningful from a biological viewpoint. Therefore, an 8-hour hold time is feasible. PLT storage in PAS-IIIM results in a PLT in vitro quality superior to that of PLTs stored in PAS-II.
Ringwald
Jürgen
J
Department for Transfusion Medicine and Haemostaseology, University Hospital of Erlangen, Erlangen, Germany. Juergen.Ringwald@trans.imed.uni-erlangen.de
Haager
Benedikt
B
Krex
Daniel
D
Zimmermann
Robert
R
Strasser
Erwin
E
Antoon
Marc
M
De Schrijver
Eddy
E
Eckstein
Reinhold
R
D001792:Blood Platelets / Q000187:drug effects*; D001793:Blood Preservation / Q000379:methods*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000032:analysis; D009997:Osmotic Pressure; D019007:P-Selectin / Q000032:analysis; D010983:Plateletpheresis / Q000592:standards*; D012996:Solutions / Q000494:pharmacology*; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000032:analysis; D053773:Transforming Growth Factor beta1
D019007:P-Selectin; D012996:Solutions; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D019344:Lactic Acid; D005947:Glucose